Evidence map›Paper›PMID 42350704›Full record

ReviewInternational journal of clinical oncology2026

High therapeutic efficacy of triplet therapy in unresectable or metastatic colorectal cancer and its optimal application strategies.

Hiroki Sakuyama, Hiroyuki Okuyama, Yoriyuki Tahara, Sena Tsukamoto, Ikuhiro Kita, Kotone Nomura, Akitsu Murakami, Yoshihiro Okita, Hironaga Satake, Takeshi Kato and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hiroki SakuyamaDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan. sakuyama.hiroki@kagawa-u.ac.jp.ORCID http://orcid.org/0009-0004-5844-7830
Hiroyuki OkuyamaDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan.
Yoriyuki TaharaDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan.
Sena TsukamotoDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan.
Ikuhiro KitaDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan.
Kotone NomuraDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan.
Akitsu MurakamiDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan.
Yoshihiro OkitaDepartment of Medical Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
Hironaga SatakeDepartment of Medical Oncology, Kochi Medical School, Nankoku, Japan.
Takeshi KatoDepartment of Surgery, NHO Osaka National Hospital, Osaka, Japan.
Akihito TsujiDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic chemotherapy for unresectable or metastatic colorectal cancer (mCRC) has improved clinical outcomes through substantial therapeutic advances. Triplet chemotherapy based on FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) has achieved high response rates and deep tumor shrinkage. In combination with molecularly targeted agents, triplet therapy plus bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has demonstrated superior efficacy compared with doublet chemotherapy plus bevacizumab. In patients with RAS/BRAF wild-type tumors, combination therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies such as cetuximab and panitumumab has also shown improved survival outcomes, although toxicity remains a major concern. Although intensified treatment is associated with increased gastrointestinal and hematologic toxicity, improved supportive care and optimized dose-adjustment strategies have enhanced the feasibility of triplet therapy in routine clinical practice. This review outlines the historical development of triplet therapy in mCRC, summarizes the major clinical trials investigating triplet chemotherapy combined with molecularly targeted agents, and discusses direct comparisons between anti-VEGF- and anti-EGFR-based strategies. Particular emphasis is placed on practical considerations for clinical implementation, including toxicity management, dose optimization, and multidisciplinary supportive care.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsBevacizumabCamptothecinCetuximabErbB ReceptorsFluorouracilHumansIrinotecanLeucovorinMolecular Targeted TherapyNeoplasm MetastasisOrganoplatinum CompoundsTreatment OutcomeVascular Endothelial Growth Factor ABevacizumabCamptothecinCetuximabErbB ReceptorsFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsVascular Endothelial Growth Factor AAnti-EGFR antibodyAnti-VEGF antibodyChemotherapyFOLFOXIRITriplet chemotherapyUnresectable or metastatic colorectal cancer (mCRC)

Identifiers

PMID42350704
PMCPMC13401560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.